SpaceX's Mobile Network Expansion Won't Hurt Incumbents in Near Term - Market Talk -- Market Talk
Dow Jones2026/10/09 09:150914 GMT - Space X's accelerated efforts to build a mobile network won't pose a near-term risk to U.S. incumbents, JPMorgan's Sebastiano Petti writes. The Elon Musk-run company agreed to buy cellular spectrum licenses from investment firm Grain Management, a significant move into the wireless service market. However, risk to established players is limited given the time and capital expenditure SpaceX needs to become more competitive, the analysts says. However, sentiment could turn against incumbents as investors adjust to the presence of a new entrant, Petti adds. Telecoms shares fall sharply in the U.S. premarket and Europe. T-Mobile shares drop 6.9% premarket, while Verizon and AT&T drop 5.8% and 6.5%, respectively. In Europe, Deutsche Telekom shares drop 7.6%. (josephmichael.stonor@wsj.com) (END) Dow Jones Newswires October 09, 2026 05:15 ET (09:15 GMT)
0914 GMT - Space X's accelerated efforts to build a mobile network won't pose a near-term risk to U.S. incumbents, JPMorgan's Sebastiano Petti writes. The Elon Musk-run company agreed to buy cellular spectrum licenses from investment firm Grain Management, a significant move into the wireless service market. However, risk to established players is limited given the time and capital expenditure SpaceX needs to become more competitive, the analysts says. However, sentiment could turn against incumbents as investors adjust to the presence of a new entrant, Petti adds. Telecoms shares fall sharply in the U.S. premarket and Europe. T-Mobile shares drop 6.9% premarket, while Verizon and AT&T drop 5.8% and 6.5%, respectively. In Europe, Deutsche Telekom shares drop 7.6%. (josephmichael.stonor@wsj.com)
(END) Dow Jones Newswires
October 09, 2026 05:15 ET (09:15 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
